首页> 外文会议>Design and quality for biomedical technologies IX >Quantitative Assessment Of Hyperspectral Imaging In Detection Of Plasmonic Nanoparticles - A Modified Contrast-detail Analysis Approach
【24h】

Quantitative Assessment Of Hyperspectral Imaging In Detection Of Plasmonic Nanoparticles - A Modified Contrast-detail Analysis Approach

机译:等离子体纳米颗粒检测中高光谱成像的定量评估-改进的对比度细节分析方法

获取原文
获取原文并翻译 | 示例

摘要

Hyperspectral reflectance imaging (HRI) is an emerging imaging modality being applied for clinical indications such as tissue oximetry, and cancer detection based on endogenous biological constituents including plasmonic nanoparticles. However, there is currently a lack of standardized test methods for objective, quantitative evaluation of HRI system performance. Contrast-detail analysis (CDA) is a phantom-based test method commonly used to evaluate medical imaging devices (e.g., mammography systems) in terms of their lower detection limit. We investigated a modified CDA (mCDA) method to quantify the detectability of gold nanoparticles by HRI systems. Silicone-based turbid phantoms containing micro-fluidic channels were developed for the mCDA tests. Polydimethylsiloxane (PDMS) phantom materials were doped with chromophores and scatterers to achieve biologically relevant optical properties (OPs). Molds were used to produce cylindrical channels of diameters 0.3 to 1.65 mm and depths of 0.2 mm inside the phantoms. Channels were filled with a mixture of hemoglobin and concentrations of gold nanorods (GNR) and measured with our HRI system. The contrast of GNRs was solved with a spectral unmixing algorithm from the reflectance spectra. The lowest detectable concentration was determined as a function of inclusion size and depth and plotted as modified contrast detail curve (mCDC). mCDCs were used to compare the detectabilities of the HRI system with different data processing algorithms. It is demonstrated that our mCDA test method involving turbid microchannel phantoms can help to elucidate the combined performance of imaging devices and plasmonic nanoparticle contrast agents. This approach may be useful for performing clinical trial standardization and device re-calibration, thus ensuring quality control and clinical performance.
机译:高光谱反射成像(HRI)是一种新兴的成像方式,可用于临床指征(例如组织血氧饱和度)和基于包括等离激元纳米粒子在内的生物成分的癌症检测。但是,目前缺乏用于对HRI系统性能进行客观,定量评估的标准化测试方法。对比度细节分析(CDA)是一种基于幻影的测试方法,通常用于根据其下限来评估医学成像设备(例如,乳房X线照相系统)。我们研究了改进的CDA(mCDA)方法来量化HRI系统对金纳米颗粒的可检测性。含有微流体通道的基于有机硅的混浊体模被开发用于mCDA测试。聚二甲基硅氧烷(PDMS)幻象材料中掺有发色团和散射体,以实现生物学相关的光学特性(OP)。模具用于在模型内部产生直径为0.3到1.65毫米,深度为0.2毫米的圆柱形通道。通道中充满了血红蛋白和金纳米棒(GNR)的混合物,并使用我们的HRI系统进行了测量。通过反射光谱中的光谱解混算法解决了GNR的对比度问题。确定最低可检测浓度为夹杂物大小和深度的函数,并绘制为修改后的对比度细节曲线(mCDC)。 mCDC用于比较HRI系统与不同数据处理算法的可检测性。结果表明,我们涉及混浊的微通道体模的mCDA测试方法可以帮助阐明成像设备和等离子纳米粒子造影剂的综合性能。此方法可能对执行临床试验标准化和设备重新校准很有用,从而确保质量控制和临床性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号